NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

BHVN

Biohaven Pharmaceutical Holding Company Ltd. New York Stock Exchange
$75.1
Open: $74.62 High: $74.69 Low: $71.51 Close: $73.65
Range: 2021-04-19 - 2021-04-20
Volume: 948,376
Market: Extended-hours
Powered by Finage Stock APIDelayed data
BHVN
Biohaven Pharmaceutical Holding Company Ltd. c/o Biohaven Pharmaceuticals, Inc. New Haven CT, 6510 http://www.biohavenpharma.com
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders.
  • CEO: Vlad Coric
  • Employees: 53
  • Sector: Healthcare
  • Industry: Biotechnology
BHVN News
Latest news about the BHVN
  • Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 22 abstracts, including three oral presentations, were accepted at the 2021 American Academy of Neurology (AAN) virtual annual meeting being held from April 17 – 22. The abstracts are available on the AAN website at https://index.mirasmart.com/AAN2021/.

    View More →
  • Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?

    Biohaven Pharmaceutical Holding Company Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

    View More →
  • Biohaven Crushes Forecasts; What's Next For Its Blockbuster Hopeful?

    Biohaven Pharmaceutical's first-quarter pre-announcement for sales of migraine treatment Nurtec ODT crushed Wall Street's expectations Wednesday. BHVN stock surged on the news.

    View More →
  • Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT

    - Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) for the first quarter of 2021.

    View More →
  • Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members

    Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Coca-Cola 600 at the Charlotte Motor Speedway. For the first time in NASCAR history, one NASCAR Cup Series team will represent the four branches of the military. Driving the Rick Ware Racing cars are #51 (Nurtec ODT) Air Force, Garret Smithley; #52 Army, Josh Bilicki; #53 Marines, JJ Yeley and #15 Navy, James Davison.

    View More →
  • The Biohaven Pharmaceutical Holding (NYSE:BHVN) Share Price Is Up 179% And Shareholders Are Boasting About It

    Biohaven Pharmaceutical Holding Company Ltd. ( NYSE:BHVN ) shareholders might be concerned after seeing the share price...

    View More →
  • Is BHVN Stock A Buy or Sell?

    In this article you are going to find out whether hedge funds think Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the […]

    View More →
  • Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant

    Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) has enrolled the first patient in a Phase 2/3 trial evaluating oral zavegepant for migraine's preventive treatment, triggering a milestone funding payment of $100 million. In August last year, Biohaven entered into a funding agreement with Royalty Pharma to secure up to $250 million to advance the development of zavegepant in migraine and other CGRP-mediated diseases. The randomized, double-blind, placebo-controlled trial will enroll approximately 2,900 people with migraines and evaluate the efficacy and safety of 100 mg and 200 mg doses of oral zavegepant. The Zavegepant program encompasses intranasal and oral formulations for migraine and non-migraine indications. Intranasal zavegepant previously demonstrated superior efficacy to placebo in a Phase 2/3 study for migraine's acute treatment. The drug is also being studied in an ongoing trial in COVID-19 infected hospitalized patients requiring supplemental oxygen. Price Action: BHVN shares are trading 4.58% lower at $63.5 on the last check Monday. See more from BenzingaClick here for options trades from BenzingaIonis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema StudyImmunityBio's Prostate Cancer Vaccine Shows Early Signs Of Clinical Activity, Durable Stable Disease© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late-stage product candidates targeting neurological diseases including rare disorders, today announced that it has enrolled the first patient in a Phase 2/3 clinical trial of oral zavegepant for the preventive treatment of migraine.

    View More →
  • Top Insider Buys Highlight for the Week of March 26

    The largest Insider Buys this week were for Perrigo Co. PLC, PennyMac Financial Services Inc., Biohaven Pharmaceutical Holding Co. Ltd. and Olo Inc.

    View More →
  • Biohaven Pharmaceutical Still Looks Unattractive Based on Its Charts

    In his first Executive Decision segment of "Mad Money" Monday, host Jim Cramer spoke with Dr. Vlad Coric, CEO of Biohaven Pharmaceutical Holding Co. , a migraine drugmaker with shares that are down from a secondary offering just last week. Coric said it has been one year since Biohaven launched Nurtec ODT for the treatment of migraine. When asked about insurance availability, Coric noted that 90% of carriers will pay for Nurtec and Biohaven has affordability options available for those that don't.

    View More →
  • Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced the pricing of its underwritten public offering of 2,686,409 of its common shares at a price to the public of $76.00 per share. In addition, Biohaven has granted the underwriter a 30-day option to purchase up to an additional 402,961 common shares at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering are expected to be approximately $200 million before deducting underwriting discounts and commissions and estimated offering expenses payable by Biohaven. The offering is expected to close on March 17, 2021, subject to satisfaction of customary closing conditions.

    View More →
  • Biohaven Announces Proposed Public Offering Of Common Shares

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative, late–stage product candidates targeting neurological diseases, including rare disorders, today announced that it has commenced an underwritten public offering of $200 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an additional $30 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

    View More →
  • 7 Pharmaceutical Stocks Working on Their Next Blockbuster

    Pharmaceutical stocks often need just a single blockbuster drug to make their fortunes. Though the definition varies, blockbuster drugs are those that generate annual sales of $1 billion or more. The biggest blockbuster drugs can even exceed $100 billion in lifetime sales. All of the companies on this list have drugs in their pipelines which could eclipse the billion dollar revenue milestone. InvestorPlace - Stock Market News, Stock Advice & Trading Tips A blockbuster drug may be enough to send a smaller company’s stock price skyrocketing. Yet, in a larger pharmaceutical firm, a succession of blockbuster drugs is necessary simply to keep prices stable. Investors should keep that in mind before buying into any of the equities on this list. 7 OTC Stocks That Could Still Run with the Big Boys Nevertheless, these pharmaceutical stocks are on track to produce blockbusters: Mirati Therapeutics (NASDAQ:MRTX) Novartis (NYSE:NVS) Biohaven Pharmaceutical (NYSE:BHVN) BioMarin Pharmaceutical (NASDAQ:BMRN) Novo Nordisk (NYSE:NVO) Daiichi Sankyo (OTCMKTS:DSNKY) arGENX (NASDAQ:ARGX) Pharmaceutical Stocks: Mirati Therapeutics (MRTX) Source: luchschenF / Shutterstock.com Mirati Therapeutics is a pharmaceutical company that focuses on oncology. Cancer costs the U.S. and the world untold sums. According to the CDC, in 2019 cancer was the second leading cause of death in the United States. Cancer comprises many different forms, and attacks multiple sites within the body. Therefore, there can be no single cure for cancer. Mirati Therapeutics is currently in the running to commercialize a therapy against a cancer that is particularly difficult to treat. Adagrasib is a drug the company has developed, which may have particular efficacy in treating non-small cell lung cancer that exhibits a specific mutation. KRAS G12C mutation positive cancers were once thought to be untreatable. However, there are several companies with promising therapies with the potential to soon hit the market. Drugs which treat once intractable diseases often become blockbusters, and there’s great potential for these types of pharmaceutical stocks. However, Mirati Pharmaceuticals is not alone in the race to treat KRAS G12C mutation positive cancers. According to FiercePharma, Amgen (NASDAQ:AMGN) looks likely to commercialize its drug, Sotorasib first. That might not be as bad as it appears. That’s because there are clear indications that Mirati Therapeutics’ Adagrasib will prove more effective in the long run. It produced a higher response than Amgen’s drug and exhibits greater tumor reduction potential. MRTX stock is down 12.5% in 2021, but analysts have it overweight with an average target price of $244.77 Novartis (NVS) Source: Shutterstock Novartis, like a few other pharmaceutical stocks, is off by roughly 12% since beginning 2021. Even so, the company has two potential blockbuster drugs in development: Kesimpta and Inclisiran. Kesimpta is an injectable drug used to treat multiple sclerosis. The drug has recently received approval. Inclisiran is used to battle high cholesterol. Inclisiran is known commercially as Leqvio. Novartis is currently launching Leqvio in Germany for patients at high risk of cardiovascular disease. The U.K. launch is set to occur in the third quarter of this year, while the U.S. launch is facing setbacks. The setbacks look to be related to production issues rather than efficacy. Inclirisan/Leqvio is manufactured at an Italian facility controlled by Corden Pharma. Process control related issues caused the FDA to delay the drug’s approval in December. 7 Stocks to Buy That Are Cheering for March Madness Novartis assumes that Kesimpta will be a growth driver during 2021. At the same time, the company recognizes that launches of both Kesimpta and Leqvio will require significant investments. Biohaven Pharmaceutical (BHVN) Source: Bukhta Yurii / Shutterstock.com Biohaven Pharmaceutical has a potential blockbuster on the market in its migraine drug called Nurtec. Nurtec helps migraine sufferers return to normal functioning for up to 48 hours with a single dose. The drug was launched commercially in the U.S. in March of 2020. Furthermore, Nurtec accounted for $63.6 million in revenues during calendar year 2020. And the drug’s sales really took off in the fourth quarter. Nurtec pulled in $35.1 million in sales, which was a 98% increase over the third quarter. Biohaven Pharmaceutical recorded no revenue in 2019. All of its 2020 revenues were attributable to Nurtec which was prescribed to 337,000 times during the period. Biohaven Pharmaceutical CEO Vlad Coric believes that Nurtec competes in an addressable market that could grow to $4 billion-$5 billion annually in the U.S. alone, which makes this one of the most compelling pharmaceutical stocks. BioMarin Pharmaceutical (BMRN) Source: Shutterstock BioMarin Pharmaceutical has an opportunity to occupy a significant corner of its market. That’s because BioMarin recently increased its production estimates in its gene therapy facility. BioMarin Pharmaceutical previously stated that it could treat up to 4,000 hemophilia A patients with its single dose drug. However, the company later upped that number to 10,000. That’s an important number because it may mean that BioMarin can treat the entire U.S. population suffering from severe hemophilia A in two years. Existing hemophilia A therapies require repeated injections. BioMarin Pharmaceuticals Valoctocogene Roxaparvovec therapy is a single dose gene therapy. If it receives FDA approval, it will provide long-lasting effects with a single dosage. The therapy costs between $2 million and $3 million. The current standard in the highly competitive hemophilia. Gene therapy costs about $700,000 annually but must be continued indefinitely. 7 of the Top Transportation Stocks to Buy Right Now Phase 3 study results for the gene therapy are expected in early 2021. Company CEO Jean-Jacques Bienaime expects 2020 revenues of around $2 billion to increase to as much as $10 billion within a decade. Novo Nordisk (NVO) Source: Shutterstock Novo Nordisk launched type-2 diabetes drug Rybelsus in 2019. Full-year 2020 sales reached $305 million, which exceeded the expectations of many analysts. Rybelsus is a glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy and is the second from Novo Nordisk. The first such therapy was Ozempic which was launched in 2018. Novo Nordisk will have a strong opportunity to dominate the market over the coming decade with both drugs. Researchers studying both semaglutide drugs have noted other interesting side effects: “Our trial showed that among adults with overweight or obesity (without diabetes), once-weekly subcutaneous semaglutide plus lifestyle intervention was associated with substantial, sustained, clinically relevant mean weight loss of 14.9%, with 86% of participants attaining at least 5% weight loss.” I cannot say if this opens up an additional sales channel in non-diabetic patients. Whether it does or does not remains irrelevant. Novo Nordisk looks to have struck gold with its newest diabetes therapies. Daiichi Sankyo (DSNKY) Source: Shutterstock Enhertu is a drug that received FDA approval in December against interstitial lung disease. Additionally, the drug is indicated against HER2- positive breast cancer. The drug is approved for use in both Japan and the United States. It is indicated for use in patients who have received two or more anti HER2 based regimens previously. As mentioned previously, a blockbuster drug is one that exceeds $1 billion in annual sales. Enhertu could eclipse that based on a prediction which pegs its 2024 sales at $2.4 billion. A monthly regimen of the drug cost $13,300 at launch. 7 Hot Stocks Ready to Ride Retail Growth SVB Leerink analyst Andrew Berens, M.D., predicted that the drug could reach peak sales of $2.5 billion annually. In one study, Enhertu reduced tumor size in 61% of cases and completely eliminated them in 6% of cases. The drug is also being evaluated for efficacy against non-small cell lung cancer and colorectal cancer. The obvious upshot here is that other potential large revenue streams may exist for Enhertu moving forward. arGEN-X (ARGX) Source: Shutterstock arGEN-X is a company and stock that had a great 2020. In early March of 2020 ARGX stock sat at $150. As of March 12, it sits above $309 per share. The company’s potential blockbuster drug is a severe autoimmune disease therapy called Efgartigimod. The drug is closest to approval for use in treating myasthenia gravis. Efartigimod is also being reviewed for two other diseases and is in Phase 3 trials. It also is being studied in a Phase 2 trial. This means the drug could receive approval for four separate diseases. Investors are keenly following, as the revenue implications are intriguing. Stifel analysts predict that peak sales of Efgartigimod for use in treating myasthenia gravis could reach $1.7 billion annually. Efgartigimod is nearest FDA approval as a therapy for that specified condition. That application alone would vault it into blockbuster territory. However, investors must remember that the drug is in two Phase 3 trials and another Phase 2 trial. That means revenue streams could peak much higher. On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner Stock Prodigy Who Found NIO at $2… Says Buy THIS Now The post 7 Pharmaceutical Stocks Working on Their Next Blockbuster  appeared first on InvestorPlace.

    View More →
  • ROCE Insights For Biohaven Pharmaceutical

    During Q4, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $35.11 million. Despite a 10.81% in earnings, the company posted a loss of $182.95 million. Biohaven Pharmaceutical collected $17.66 million in revenue during Q3, but reported earnings showed a $165.10 million loss. What Is ROCE? Changes in earnings and sales indicate shifts in Biohaven Pharmaceutical's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Biohaven Pharmaceutical posted an ROCE of 0.83%. It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent performance, but several factors could affect earnings and sales in the near future. View more earnings on BHVN ROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows Biohaven Pharmaceutical is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth. In Biohaven Pharmaceutical's case, the positive ROCE ratio will be something investors pay attention to before making long-term financial decisions. Q4 Earnings Insight Biohaven Pharmaceutical reported Q4 earnings per share at $-2.69/share, which beat analyst predictions of $-2.97/share. See more from BenzingaClick here for options trades from BenzingaBenzinga's Top Ratings Upgrades, Downgrades For March 11, 2021Recap: Biohaven Pharmaceutical Q4 Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Genpharm announced today that NURTEC® ODT (rimegepant) was approved by the United Arab Emirates Ministry of Health and Prevention for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

    View More →
  • Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") announced today that more than 50% of participants have been enrolled in the verdiperstat regimen of HEALEY ALS Platform Trial, which is evaluating the efficacy of several treatments including verdiperstat in people with amyotrophic lateral sclerosis ("ALS"). Verdiperstat is a potential first-in-class, brain-penetrant, selective inhibitor of myeloperoxidase in development by Biohaven for the treatment of neurodegenerative diseases, including ALS and multiple system atrophy.

    View More →
  • Biohaven's NURTEC® ODT Approved In Israel For Acute Treatment Of Migraine

    Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") and Medison Pharma announced today that NURTEC® ODT (rimegepant) was approved by the Israeli Ministry of Health for the acute treatment of migraine with and without aura in adults. NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT) approved for the acute treatment of migraine.

    View More →
  • 2 ‘Strong Buy’ Stocks Insiders Are Snapping Up

    In a casino, if you play long enough, the House always wins; this is just a matter of probabilities and available resources. It’s different in the stock market, even though there is a tendency to refer to stock investing as a game. Smart investors don’t have to ‘beat the house’ to come out ahead; this is not a zero-sum game. Rather, it’s a game of strategy. Successful investors will look for some edge, an ‘in’ that will lead them toward winning investments. This search naturally leads some investors to the corporate insiders – company officers and board members whose positions give them an inside track on the background that will impact stock prices. To the great good fortune of the investing public, the regulatory authorities require that inside traders regularly publish the stock transactions they make in the companies they run. This generates a wealth of information from the SEC, and TipRanks makes it easy for investors to use the raw data, with the Insiders’ Hot Stocks tool. This tool features a variety of filters letting investors search stocks by trading strategies, making sense of a difficult data set. We’ve used the data to pinpoint a pair of stocks showing two clear signals for investors: A Strong Buy analyst consensus rating, and a recent ‘informative buy’ from a company insider. Fiserv, Inc. (FISV) We will start with Fiserv, a financial tech company providing services to banks, credit unions, securities brokers, finance companies, and retailers. The company’s products include payment services, account and billing solutions, customer management and online banking, risk compliance tools, and data analytics. In short, Fiserv is a full-service fintech, with customers in a wide range of sectors, including banks, government, healthcare, insurance, telecom, and utilities. After seeing revenues slide in 1H20, Fiserv bounced back in the second half. The top line came in at $3.79 billion for Q3 and $3.83 billion for Q4; full-year revenues for 2020 reached $13.9 billion. While these were considered solid numbers, and beat expectations, the coronavirus impact was felt in year-over-year declines. Earnings, however, fared better. Fiserv registered a profit of $4.42 per share in 2020, for a 12% increase over the prior year. On the insider front, the ‘informative buy’ here was made by Denis O’Leary, Director and Chairman of the Board at Fiserv. O’Leary spent $1.01 million on 9,100 shares of FISV. Turning to the analyst community, Mizuho’s Dan Dolev believes the company has a lot going for it and a bright future. “Following marked organic outperformance vs. peers in 2020, we view FISV on track to impress again in 2021, with strong growth across the board… Investors often think of FISV as a legacy operator with fewer analytic capabilities than next-gen firms. This is not true, in our view… FISV deploys advanced analytics to measure every client interaction, investing in automation to improve engagement. While ‘the journey never ends,’ FISV is already seeing strong success in these efforts, seeing just low-single-digit senior level attrition,” Dolev commented. In line with his optimistic approach, Dolev rates FISV a Buy, and his $160 price target implies a 38% upside for the year ahead. (To watch Dolev’s track record, click here) Overall, there are no fewer than 19 reviews on file for Fiserv, and they break down 17 to 2 in favor of Buys versus Holds. This indicates a broad view on Wall Street that the stock is a buying proposition, and makes the consensus rating a Strong Buy. Shares are priced at $115.80, and their $134 average price target suggests room for ~16% growth on the one-year time horizon. (See FISV stock analysis on TipRanks) Biohaven Pharmaceutical Holding (BHVN) From fintech we move to the pharmaceutical sector. Biohaven focuses on neurological and neuropsychiatric diseases, and has a pipeline with therapies in various stages of development, and one treatment which has already gained FDA approval. Last year, Biohaven's NURTEC was given the go ahead for the acute treatment of migraine in adults and has been performing well since its launch. The treatment has another upcoming catalyst on the horizon. The FDA has accepted an sNDA (supplemental new drug application) for the prevention of migraine and a PDUFA date is expected in the second quarter. Turning to the insider trades, on March 2, John Childs, one of the company’s Directors, paid $851,370 for a bloc of 10,000 shares. His display of confidence gets the backing of H.C. Wainwright’s Douglas Tsao. The 5-star analyst anticipates the US approval of NURTEC in preventative migraine followed by an immediate launch. Tsao is also impressed by NURTEC's “continued linear growth.” “Despite being on the market for only about one year, NURTEC continues to take share from triptans and even mAbs used in preventative treatment, though the share is still relatively small, suggesting plenty of room for growth,” Tsao said. “Importantly, neurologist and patient attitudes towards Nurtec are overwhelmingly positive, with 58% of patients satisfied compared to just 37% on Ubrelvy, again suggesting robust growth potential based on the drug’s best-in-class attributes.” Accordingly, Tsao has a Buy rating on BHVN shares, to go alongside a $111 price target. This figure implies a 43% upside from current levels. (To watch Tsao’s track record, click here) Biohaven also has plenty of support amongst Tsao’s colleagues. The analyst consensus rates the stock a Strong Buy, based on 8 Buys and 1 Hold. At $103.13, the average price target implies gains of 33% over the next 12 months. (See BHVN stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

    View More →
  • Biohaven (BHVN) Q4 Earnings Miss, Nurtec Uptake Promising

    Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.

    View More →